NSCLC

[Oncology Letters] The molecular mechanism underlying the role of FOXD3‑AS1 in cancer development has not yet been fully elucidated. Researchers focused on non‑small cell lung cancer in order to gain insight into how FOXD3‑AS1 drives cancer progression.

[Kintor Pharmaceutical Limited] Kintor Pharmaceutical Limited announced that the company has enrolled and dosed its first patient with advanced or refractory solid tumors in a clinical trial of ALK-1 antibody in combination with KN046.

[Galecto, Inc.] Galecto, Inc. announced that it has entered into a clinical trial supply agreement with Roche to explore the combination of GB1211, Galecto’s oral galectin-3 inhibitor, with Roche’s PD-L1 checkpoint inhibitor atezolizumab in Galecto’s planned Phase IIa trial in non-small-cell lung cancer

[Cancer Cell International] The authors investigated the role of ASAP1 Intronic Transcript 1 (ASAP1-IT1) in cancer cell stemness of non-small cell lung cancer.

[Cancer Medicine] The function of CAMSAP3 on the regulation of cellular senescence-associated phenotypes in human non-small cell lung cancer H460 cells were determined in CAMSAP3 deletion (H460/C3ko) cells.

[Cell Death & Disease] Scientists evaluated the specific regulatory mechanisms of exosomal miR-338-3p/CHL1/MAPK signaling pathway axis in NSCLC. In vitro MTS and apoptotic assays were used to investigate the functions of CHL1 and exosomal miR-338-3p in NSCLC progression.